Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 10, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The filing details a specific transaction on May 2, 2006, where 10 Ordinary shares were sold on behalf of participants in the SmithKline Beecham Unapproved Share Matching Plan. The sale price was GBP 15.463 per share. This transaction was executed by the Administrators of the SmithKline Beecham Employee Benefit Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that Mr. J Heslop, a director of the company, holds an interest in the shares held within the Trust in the same capacity as other non-US employees or former employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total volume of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the 10-share transaction.
- Confirm the current status of the SmithKline Beecham Unapproved Share Matching Plan.
- Review the full list of directors and their specific interests in the Trust beyond Mr. J Heslop.